Xylem: Growth Fully Justifies The High Multiple

Xylem (XYL), the market leader in clean water solutions, demonstrates strong growth prospects despite its 29.7x current earnings multiple, underpinned by robust secular demand for water infrastructure amid global scarcity. The company projects maintaining approximately 6% revenue growth, bolstered by synergies from the Evoqua acquisition and market share expansion. Notably, Xylem has significantly outpaced its margin expansion goals, boosting EBITDA margins from 15% to 20%, with further gains anticipated from operational optimization and price increases due to low customer price elasticity. This consistent, non-cyclical growth, with analysts projecting strong double-digit earnings, positions Xylem favorably, suggesting it warrants a premium relative to the more cyclical S&P 500.

Analysis

Xylem Inc. (XYL) presents a compelling growth narrative centered on significant margin expansion and stable, secular demand for its water solutions. Despite a premium valuation at 29.7 times its freshly raised earnings guidance of $4.70-$4.85, the company's performance appears to justify the multiple. The core of the investment thesis is not its top-line growth, which is projected to be a steady 6% annually, but its aggressive margin enhancement. Xylem has already expanded EBITDA margins from approximately 15% to 20%, substantially outpacing its stated goal of 100 basis points of annual improvement. This was achieved through operational efficiencies, including paring back on negative-profitability sales, and is expected to continue via strong pricing power, as its services are essential and face low customer price elasticity. The 2023 acquisition of Evoqua for $7.65B, though expensive at 47x forward earnings, is proving to be accretive through cost and future revenue synergies. While Xylem's normalized earnings growth is projected to be in the low double-digits, comparable to the S&P 500, its growth is non-cyclical and enduring, unlike the market's more volatile earnings profile, suggesting its consistency may be undervalued. Key risks to this outlook are regulatory pressures on its water utility clients and the potential for higher interest rates to dampen infrastructure spending.

Key Decisions for Investors

• Investors should assess whether Xylem's non-cyclical, secular growth profile warrants a premium valuation compared to the broader market, which exhibits similar growth rates but with higher cyclicality.
• Monitor the company's ability to sustain or expand its EBITDA margins beyond the current 20% level, as continued margin improvement is the central pillar of the bull thesis.
• Track regulatory developments for water utilities and the macroeconomic interest rate environment, as these are the primary external risks that could negatively impact Xylem's revenue growth and capital deployment.
• Focus on management's execution and commentary regarding revenue synergies from the Evoqua integration, as this represents a key potential upside to the baseline 6% revenue growth forecast.